SNCA and Parkinson disease: Recent literature shows that the use of small molecules against α-synuclein aggregation is safe and efficient by increasing autophagy/lysosomal flux than other PD therapies [40], for instance, ambroxol or Cu(II)ATSM small molecule α-synuclein target drugs being tested in the pipeline of clinical trials, and could be successful drugs in future.